{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Progenitor+Cells&page=93",
    "query": {
      "condition": "Progenitor Cells",
      "page": 93
    },
    "page_size": 10
  },
  "pagination": {
    "page": 93,
    "page_size": 10,
    "total_count": 3286,
    "total_pages": 329,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Progenitor+Cells&page=94&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Progenitor+Cells&page=92&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-03T15:13:17.257Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02010606",
      "title": "Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma",
        "Glioblastoma Multiforme",
        "Glioma",
        "Astrocytoma",
        "Brain Tumor"
      ],
      "interventions": [
        {
          "name": "Dendritic cell vaccination, in addition to standard temozolomide chemotherapy and involved field radiation therapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Cedars-Sinai Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2014-01-08",
      "completion_date": "2021-07-10",
      "has_results": false,
      "last_update_posted_date": "2021-11-22",
      "last_synced_at": "2026-11-03T15:13:17.257Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02010606"
    },
    {
      "nct_id": "NCT04876248",
      "title": "Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Plasma Cell Myeloma"
      ],
      "interventions": [
        {
          "name": "Belantamab Mafodotin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2024-08-19",
      "completion_date": "2027-07-29",
      "has_results": false,
      "last_update_posted_date": "2026-10-16",
      "last_synced_at": "2026-11-03T15:13:17.257Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04876248"
    },
    {
      "nct_id": "NCT00183248",
      "title": "Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Kidney Transplantation",
        "Kidney Disease",
        "Kidney Failure"
      ],
      "interventions": [
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Donor bone marrow stem cell infusion",
          "type": "PROCEDURE"
        },
        {
          "name": "Kidney transplant",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 9,
      "start_date": "2004-09",
      "completion_date": "2009-11",
      "has_results": true,
      "last_update_posted_date": "2012-10-02",
      "last_synced_at": "2026-11-03T15:13:17.257Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00183248"
    },
    {
      "nct_id": "NCT02282215",
      "title": "Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Neutropenia",
        "Infection"
      ],
      "interventions": [
        {
          "name": "CLT-008",
          "type": "BIOLOGICAL"
        },
        {
          "name": "G-CSF",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Cellerant Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 163,
      "start_date": "2014-12",
      "completion_date": "2017-09-22",
      "has_results": false,
      "last_update_posted_date": "2018-09-27",
      "last_synced_at": "2026-11-03T15:13:17.257Z",
      "location_count": 22,
      "location_summary": "La Jolla, California • Los Angeles, California • San Francisco, California + 16 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02282215"
    },
    {
      "nct_id": "NCT02026934",
      "title": "CliniMACS® CD34+ Reagent System for Expanded Access Use",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Graft-Versus-Host Disease(GVHD)",
        "Anemia Due to Disturbance of Proliferation and/or Differentiation of Hematopoietic Stem Cells",
        "Graft Failure",
        "Delayed Graft Function"
      ],
      "interventions": [
        {
          "name": "CliniMACS CD34 Reagent System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Joseph Antin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2013-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2016-11-21",
      "last_synced_at": "2026-11-03T15:13:17.257Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02026934"
    },
    {
      "nct_id": "NCT00003064",
      "title": "Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "Primary Peritoneal Cavity Cancer"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "etoposide phosphate",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "thiotepa",
          "type": "DRUG"
        },
        {
          "name": "topotecan hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Herbert Irving Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 30,
      "start_date": "1997-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-01-06",
      "last_synced_at": "2026-11-03T15:13:17.257Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003064"
    },
    {
      "nct_id": "NCT04640987",
      "title": "Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hematologic Diseases"
      ],
      "interventions": [
        {
          "name": "Allogeneic Stem Cell Transplant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CliniMACS Prodigy System",
          "type": "DEVICE"
        },
        {
          "name": "T-allo10 cells addback",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Porteus, Matthew, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "1 Month to 45 Years"
      },
      "enrollment_count": 22,
      "start_date": "2021-02-10",
      "completion_date": "2029-03",
      "has_results": false,
      "last_update_posted_date": "2026-01-08",
      "last_synced_at": "2026-11-03T15:13:17.257Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04640987"
    },
    {
      "nct_id": "NCT01658904",
      "title": "Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma",
        "Leukemia, Plasma Cell"
      ],
      "interventions": [
        {
          "name": "Carfilzomib",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 3,
      "start_date": "2012-07",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2016-06-01",
      "last_synced_at": "2026-11-03T15:13:17.257Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01658904"
    },
    {
      "nct_id": "NCT00088543",
      "title": "Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia (AML)",
        "Acute Lymphocytic Leukemia (ALL)",
        "Graft vs. Host Disease (GvHD)"
      ],
      "interventions": [
        {
          "name": "Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 60,
      "start_date": "2004-03",
      "completion_date": "2006-04",
      "has_results": false,
      "last_update_posted_date": "2015-03-18",
      "last_synced_at": "2026-11-03T15:13:17.257Z",
      "location_count": 12,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Gainesville, Florida + 8 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00088543"
    },
    {
      "nct_id": "NCT02659943",
      "title": "T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma, B-Cell",
        "Lymphoma, Non-hodgkins"
      ],
      "interventions": [
        {
          "name": "Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "73 Years",
        "sex": "ALL",
        "summary": "18 Years to 73 Years"
      },
      "enrollment_count": 27,
      "start_date": "2016-01-21",
      "completion_date": "2022-12-31",
      "has_results": true,
      "last_update_posted_date": "2023-04-19",
      "last_synced_at": "2026-11-03T15:13:17.257Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02659943"
    }
  ]
}